Riskpilot← Back to searchSign inGet full accessJL Neuro AB
ABActiveOrg 5591944748Föreningsgatan 2Other education n.e.c. · NACE 8559Est. 20191 employees
Revenue 2025
SEK 423K
-2% vs 2024
EBITDA margin
95.2%
-2% vs 2024
Equity ratio
72.3%
Financial strength
Net profit 2025
SEK 318K
+30% vs 2024
| Revenue | SEK 423K | -2% |
| EBITDA | SEK 403K | -2% |
| Net profit | SEK 318K | +30% |
| Total assets | SEK 1,5M | +30% |
| Equity | SEK 1,1M | +41% |
| Employees | 1 | — |
Legal name
JL Neuro AB
Org number
5591944748
Legal form
Aktiebolag
NACE code
8559 · Other education n.e.c.
Founded
11 februari 2019
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Medicinsk vård. Medicinsk och vetenskaplig konsultation. Föreläsningar. Handledning och gruppundervisning. Research och författande av artiklar och rekommendationer. Verksamhetsledning.
Address
Föreningsgatan 2
Email
jan.lycke@neuro.gu.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 413 | 264 | 425 | 433 | 423 |
| Staff expenses | — | — | — | — | −0 |
| EBITDA | 424 | 267 | 408 | 411 | 403 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 424 | 267 | 408 | 411 | 403 |
| Net financials | −1 | −0 | 0 | −0 | −1 |
| Profit before tax | 319 | 266 | 308 | 311 | 402 |
| Tax | −66 | −55 | −64 | −65 | −84 |
| Net profit | 253 | 211 | 244 | 245 | 318 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 577 | 532 | 800 | 1 159 | 1 507 |
| Equity | 358 | 382 | 526 | 772 | 1 089 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 115 | 45 | 69 | 83 | 113 |
| Total debt | 115 | 45 | 69 | 83 | 113 |
EBITDA margin
95.2%
This company
15.8%
Market median
+503% vs market
20212025
Equity ratio
72.3%
This company
38.2%
Market median
+89% vs market
20212025
Return on equity
29.2%
This company
18.4%
Market median
+59% vs market
20212025
Net profit margin
75.2%
This company
8.1%
Market median
+828% vs market
20212025
Asset turnover
0.28×
This company
1.12×
Market median
-75% vs market
20212025
Debt / equity
0.38×
This company
0.62×
Market median
+39% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of JL Neuro AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maja Elly Lycke | Deputy Board Member | 0 companies |
| Jan Nils Lycke | Board of Directors | 0 companies |